Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bausch & Lomb PureVision 30-Day Indication Receives FDA Go-Ahead

This article was originally published in The Gray Sheet

Executive Summary

A hearing to address patent infringement allegations by Bausch & Lomb over Ciba Vision's extended-wear contact lenses will take place in January in Rochester, New York federal court, according to B&L

You may also be interested in...



B&L Relying On PureVision Growth To Offset Refractive Market Decline

Bausch & Lomb says it is counting on product introductions that incorporate new technologies, such as the PureVision continuous-wear lenses, to offset lagging sales of older lines as the firm works to stabilize its financial performance

B&L Relying On PureVision Growth To Offset Refractive Market Decline

Bausch & Lomb says it is counting on product introductions that incorporate new technologies, such as the PureVision continuous-wear lenses, to offset lagging sales of older lines as the firm works to stabilize its financial performance

Ciba Vision's Focus

Extended-wear, disposable Focus Night & Day soft contact lenses will be priced "competitively" with the cost of wearing and cleaning ordinary disposables, the Novartis unit says following FDA approval Oct. 12. The lenses are the first to be approved for continuous 30-day wear, as opposed to the conventional seven-day maximum. Made of lotrafilcon A, the Focus is available for eyes +0.25 diopters to +6 D in 0.25 D increments, -0.25 D to -8 D eyes in 0.25 D steps and -8.5 D to -10 D eyes in 0.5 D steps. FDA's Ophthalmic Devices Panel recommended approval in July (1"The Gray Sheet" July 23, 2001, p. 27). A required postmarket study will evaluate long-term risk of infection

Related Content

UsernamePublicRestriction

Register

MT015762

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel